Invasive Infections with Multidrug-Resistant Yeast Candida auris, Colombia

• Published in: Emerging infectious diseases Vol. 23; no. 1; pp. 162 - 164
• Main Authors: Morales-Lopez, Soraya E, Parra-Giraldo, Claudia M, Ceballos-Garzon, Andres, Martinez, Heidys P, Rodriguez, Gerson J, Alvarez-Moreno, Carlos A, Rodriguez, Jose Y
• Format: Journal Article
• Language: English
• Published: United States U.S. National Center for Infectious Diseases 01.01.2017; Centers for Disease Control and Prevention
• Subjects: Adolescent; Adult; Aged; Americas; Antifungal agents; Antifungal Agents - therapeutic use; antimicrobial resistance; Candida - chemistry; Candida - drug effects; Candida - isolation & purification; Candida - pathogenicity; Candida auris; candidemia; Candidiasis, Invasive - diagnosis; Candidiasis, Invasive - drug therapy; Candidiasis, Invasive - microbiology; Candidiasis, Invasive - mortality; Child; Child, Preschool; Colombia; Delayed Diagnosis; Drug resistance in microorganisms; Drug Resistance, Multiple, Fungal; Etest; Female; France; Fungemia - diagnosis; Fungemia - drug therapy; Fungemia - microbiology; Fungemia - mortality; Health aspects; Hospital patients; Humans; Infant; Infant, Newborn; Infection; Invasive Infections with Multidrug-Resistant Yeast; Letter; Letters to the Editor; Male; Microbial Sensitivity Tests; Middle Aged; Mortality; Mycoses; Survival Analysis; VITEK; France; Colombia; Americas; Candida auris; Colombia; Etest; antimicrobial resistance; fungi; VITEK; fungemia; candidemia
• ISSN: 1080-6040; 1080-6059
• DOI: 10.3201/eid2301.161497

Candida auris is an emerging multidrug-resistant fungus that causes a wide range of symptoms. We report finding 17 cases of C. auris infection that were originally misclassified but correctly identified 27.5 days later on average. Patients with a delayed diagnosis of C. auris had a 30-day mortality rate of 35.2%.